#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Philadelphia positive chronic myeloid leukaemia Polyneuropathy Cystic fibrosis Osteosarcoma Follicular lymphoma Pulmonary alveolar haemorrhage Chronic graft versus host disease Pleural mesothelioma Retinopathy of prematurity Fabry's disease Ependymoma Lymphangiosarcoma Craniopharyngioma Cutaneous T-cell lymphoma refractory Thalassaemia More trials…

    Learn about Rare Diseases

    Toxic epidermal necrolysis – Life with Disease Pleomorphic leiomyosarcoma – Life with Disease Mucous membrane pemphigoid – Basic Information Haemophilia B with anti factor IX – Life with Disease Sjogren’s syndrome Mantle cell lymphoma stage III Andersen-Tawil syndrome – Basic Information Mastocytosis – Trials in Disease Wolfram syndrome – Trials in Disease Atypical teratoid/rhabdoid tumour of CNS – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Garetosmab Astegolimab Nandrolone Decanoate HTL0022537 Msv-Allo Regn9933 Naproxen Sodium L-ARGININE [89Zr]Bms-986279 Sibeprenlimab Glepaglutide Riluzole Sodium Phenylbutyrate Escitalopram Oxalate Potassium LIPASE Human Von Willebrand Factor ATUMELNANT BNT327 Idecabtagene Vicleucel More therapies…

    Learn about Your Condition

    Pulmonary congestion Turner's syndrome Naevoid melanoma Bacterial vaginosis Perineal injury Metabolic syndrome Sleep disorder Chorea Pancreatic carcinoma stage IV Spondylolisthesis Diffuse large B-cell lymphoma Conjunctivitis allergic Pulmonary fibrosis Cleft lip and palate Laryngeal cancer stage III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Dalbavancin versus standard drug combination for treatment of infective endocarditis caused by Gram‑positive cocci in adult patients

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Endocarditis bacterial
    Investigated Drugs:
    • Ampicillin
    • Cefaclor
    • Cefalexin
    Germany

  • Safety and Tolerability of Inhaled KB707 with or without Docetaxel in Patients with Advanced Lung Solid Tumors

    Not yet recruiting

    1 1 1 1
    Investigated Drugs:
    • Docetaxel
    France Spain

  • Clarithromycin to prevent secondary infections in adult patients with community-acquired pneumonia-related sepsis

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Sepsis
    Investigated Drugs:
    • Water For Injection
    • Clarithromycin
    • Glucose Monohydrate
    Greece

  • Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Pulmonary hypertension
    Investigated Drugs:
    • Treprostinil Palmitil
    Austria Belgium Czechia Denmark France Germany +6

  • Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer

    Not yet recruiting

    3 1
    Investigated Drugs:
    • Taletrectinib
    Belgium France Germany Italy Spain

  • Phase 2 Study of PF-08634404 with Carboplatin and Etoposide in Adults with Untreated Small Cell Lung Cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Etoposide
    France Italy Spain
Previous Page
1 … 686 687 688 689 690 … 1,657
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!